Anti-tumor small molecule compound taking FGL2 as target spot and application of anti-tumor small molecule compound

The small molecule compounds C16H17N3O2 and C14H16N2O2S2 interfere with the binding of FGL2 to FcγRIIB, solving the problem of immunosuppression of FGL2 in tumors and hepatitis, promoting T cell function, inhibiting immunosuppressive cells, and achieving the therapeutic effect of tumors and hepatitis.

CN118930486AActive Publication Date: 2024-11-12ARMY MEDICAL UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410958026.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-12
Estimated Expiration
2044-07-17

AI Technical Summary

Technical Problem

FGL2 is highly expressed in tumor tissues, promoting the activity of immunosuppressive cells, leading to tumor immune escape and aggravation of hepatitis, and it is difficult for the prior art to effectively interfere with its functions.

Method used

Small molecule compounds C16H17N3O2 and C14H16N2O2S2 were screened for binding to the fibrinogen-related domain of FGL2 protein, interfering with the binding of FGL2 to FcγRIIB, promoting T cell function and inhibiting the activation of immunosuppressive cells, thereby inducing tumor clearance.

Benefits of technology

These small molecule compounds can effectively insert the C-terminal domain of FGL2 protein, interfere with the FGL2-FcγRIIB signaling pathway, promote T cell proliferation and differentiation, inhibit immunosuppressive cells, and induce tumor clearance, and show that in liver cancer and severe hepatitis. Therapeutic potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930486A_ABST
    Figure CN118930486A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biomedicine, and discloses an anti-tumor small molecule compound taking FGL2 as a target spot, and the anti-tumor small molecule compound comprises any one of small molecule compounds C16H17N3O2 and C14H16N2O2S2; the invention also discloses an application thereof. According to the invention, small molecular compounds C16H17N3O2 and C14H16N2O2S2 which can be specifically combined with FGL2 are found, and the two small molecular compounds can be inserted into a pocket of a fibrinogen related structural domain consisting of 233 amino acids at the C-terminal of FGL2 protein and are tightly combined; the two small molecule compounds interfere with the combination of the FGL2 and a receptor Fc [gamma] RIIB of the FGL2, so that the anti-CD3 antibody and the anti-CD28 antibody are promoted to induce the proliferation, differentiation and other activities of T cells, the functions of the T cells are promoted, activation of myeloid-derived immunosuppressive cells (MDSCs) is interfered, tumor removal is further induced, and the compound can be applied to tumor diseases with high expression of the FGL2 and has a good application prospect. For example, related diseases such as liver cancer and severe hepatitis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedical technology and relates to an anti-tumor small molecule compound with FGL2 as a target and an application thereof. Background Art

[0002] Fibrinogen-like protein 2 (FGL2) belongs to the fibrinogen-related protein superfamily, also known as FGL2 prothrombinase. In the absence of coagulation factors FVII or FX, FGL2 can directly cleave prothrombin into thrombin and promote thrombosis. There are two forms of FGL2 protein. Transmembrane FGL2 (mFGL2) is only expressed in macrophages, endothelial cells and intestinal embryonic trophoblast cells. However, under viral infection or cytokine induction, endothelial cells, T cells, especially CD4 + CD25 + Regulatory T cells (Treg) and macrophages can highly express secretory FGL2 (sFGL2). Structurally, the C-terminus of the FGL2 protein has a fibrinogen-related domain (FRED) composed of 233 amino acids, which is the recognition region of FGL2 and the FcγRIIb receptor; it is also the site where FGL2 binds to calcium and substrates; and its N-terminus is mainly composed of some linearly arranged hydrophobic amino acids and contains a transmembrane region and serine Ser89 that can promote coagulation activity, which can quickly start the coagulation process. It has been confirmed that mFGL2 has procoagulant activity and sFGL2 mainly mediates T cell damage and even promotes CD8 + T cell apoptosis. HBV, HCV and murine hepatitis virus-3 (MHV-3) can stimulate infected hepatocytes or macrophages to upregulate the expression of mFGL2, causing intrahepatic thrombosis and tissue necrosis; in acute transplant rejection, mFGL2 induces coagulation events in the transplanted organ, so targeting mFGL2 is one of the effective strategies to intervene in transplant rejection. In addition, studies have found that sFGL2 can inhibit dendritic cell maturation (downregulating CD80 and MHC-II expression) and induce CD4 + T cell anergy; sFGL2-FcγRIIb signaling pathway can activate the downstream BTK-JNK pathway to promote CD8 + Apoptosis of T cells and B cells. In addition, some studies have found that sFgl2 secreted by Treg is the molecular basis for its immunosuppressive function. FcγRIIB is expressed on the surface of various cells and can mediate the regulation of various immune cell functions, such as inhibiting macrophage killing cells, phagocytosis, antibody-dependent cell-mediated cytotoxicity (ADCC) and T cell proliferation and activation.

[0003] Some experimental results of the inventors show that sFgl2 inhibits neutrophil infiltration, promotes its apoptosis and clearance by macrophages after binding to its ligand FcγRIIB, and promotes the regression of peritonitis in mice. These results all indicate that FGL2 plays a key role in virus-induced severe hepatitis and provides a new target for the treatment of inflammatory diseases. Studies have found that a large amount of FGL2 is expressed in tumor tissues including melanoma, ovarian cancer, cervical cancer, lung cancer, kidney cancer, liver cancer, colorectal cancer, breast cancer and prostate cancer. FGL2 is highly expressed in human malignant tumor tissues and is mainly distributed in tumor parenchymal cells, interstitial infiltrating cells, tumor vascular endothelial cells and extracellular matrix (EMC), and this high expression has an anatomical position relationship with fibrin deposition. It is also found that its ligand FcγRIIB is mainly highly expressed on myeloid-derived immunosuppressive cells (MDSCs) and T cells. The growth of subcutaneous tumors in Fgl2 knockout mice is inhibited, the M1 macrophages and DCs infiltrating tumor tissues increase, and the infiltration of MDSCs decreases. Further studies found that the infiltration of granulocyte-derived MDSCs subsets in tumor tissues of the Fgl2 KO group was significantly reduced. In addition, the ability of Fgl2 KO HPCs to differentiate into granulocyte / macrophage precursor cells (GMPs) was weakened. In particular, the study found that FGL2 neutralizing antibodies could significantly reduce the level of MDSCs in tumors and increase CD8 + The number of T cells can be reduced, inhibiting tumor growth. At the same time, the use of Fgl2 neutralizing antibodies and PD-1 neutralizing antibodies can further reduce the content of MDSCs in tumors and activate anti-tumor immunity. The results show that Fgl2 plays a key role in tumor immune escape.

[0004] Studies on the liver have found that the level of hFgl2 in the liver tissue of patients with severe chronic hepatitis B is higher than that in patients with mild and moderate chronic hepatitis B, suggesting that hFgl2 may play a role in aggravating liver damage in chronic hepatitis B. In addition, the expression level of hFgl2 in the liver tissue of patients with severe hepatitis was found to be positively correlated with serum bilirubin. In addition, fibrin deposition and microthrombosis were found in the adjacent tissues of hFgl2-highly expressed cells in the liver tissue of severe hepatitis B. In particular, the study also found that hFgl2 was highly expressed in liver cancer tissue, and its level was higher than that of mild and moderate chronic hepatitis B groups. It suggests that hFgl2 may be involved in the occurrence, development and activity of severe hepatitis caused by liver cancer and HBV infection. Therefore, screening small molecule compounds that interfere with its function by targeting FGL2 will provide a new means for clinical treatment. Summary of the invention

[0005] In view of this, the purpose of the present invention is to use FGL2 as a target and screen small molecule compounds that can specifically bind to it. The small molecule compounds can interfere with the Fgl2-FcγRIIB inhibitory signaling pathway, thereby promoting the function of T cells and interfering with the activation of myeloid-derived immunosuppressive cells (MDSCs), thereby inducing tumor clearance.

[0006] In order to achieve the above object, the present invention provides the following technical solutions:

[0007] An anti-tumor small molecule compound targeting FGL2, wherein the small molecule compound is any one of C16H17N3O2 and C14H16N2O2S2.

[0008] Furthermore, the tumor is a liver tumor.

[0009] Furthermore, the small molecule compound is used at a concentration of 1 μM.

[0010] Furthermore, the small molecule compound is tightly bound to the FGL2 protein by inserting into the pocket of the fibrinogen-related domain composed of 233 amino acids at the C-terminus of the FGL2 protein.

[0011] To achieve the above objectives, the present invention also provides the use of small molecule compounds in the preparation of drugs for treating tumor diseases with high expression of FGL2.

[0012] Furthermore, the drug interferes with the binding of FGL2 to its receptor FcγRIIB by binding to FGL2, thereby promoting T cell proliferation and differentiation.

[0013] Furthermore, the drug interferes with the binding of FGL2 to its receptor FcγRIIB by binding to FGL2, thereby interfering with the activation of myeloid-derived immunosuppressive cells, thereby inducing tumor clearance.

[0014] Furthermore, the drug can also be used to treat severe hepatitis.

[0015] The beneficial effect of the present invention is that: the present invention discovers a small molecule compound C that can specifically bind to FGL2 16 H 17 N3O2 and C 14 H 16N2O2S2, the above two small molecule compounds can insert into the pocket of the fibrinogen-related domain composed of 233 amino acids at the C-terminus of the FGL2 protein and bind tightly; the above two small molecule compounds interfere with the binding of FGL2 to its receptor FcγRIIB, thereby promoting the activities of anti-CD3 antibodies + anti-CD28 antibodies to induce T cell proliferation and differentiation, thereby promoting the function of T cells and interfering with the activation of myeloid-derived immunosuppressive cells (MDSCs), thereby inducing tumor clearance, and can be applied to tumor diseases with high expression of FGL2, such as liver cancer, severe hepatitis and other related diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention will be described in detail below in conjunction with the accompanying drawings, wherein:

[0017] Figure 1 is a diagram of the protein structure model of hFGL2 constructed in Example 1;

[0018] Figure 2 This is a list of potential small molecule compounds that can bind to FGL2 and insert into the FGL2 pocket in Example 1;

[0019] Figure 3 The small molecule compounds in Example 1 interfere with the sFGL2-FcγRIIB pathway on CD3 + Results of the regulatory effect on T cell proliferation;

[0020] Figure 4 The figure is the result of drugability analysis of the small molecule compound in Example 1;

[0021] Figure 5 C in Example 1 14 H 16 The results of the binding effect of N2O2S2 compounds on mouse FGL2;

[0022] Figure 6 This is a picture of the tumor size observed by in vivo imaging in Example 2;

[0023] Figure 7 This is a graph showing the inhibitory effects of the two small molecule compounds in Example 2 on a liver cancer transplant tumor model. DETAILED DESCRIPTION

[0024] The following describes the embodiments of the present invention by specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention. It should be noted that the illustrations provided in the following embodiments only illustrate the basic concept of the present invention in a schematic manner, and the following embodiments and features in the embodiments can be combined with each other without conflict.

[0025] Embodiment 1:

[0026] Since there is no report on the structure of human and mouse FGL2 proteins, the inventors used Discovery studio and alphafold 2 to predict the structure of human fibroblast hFGL2 protein, focusing on its FRED domain; further constructed a protein structure model of the hFGL2 catalytic site, and predicted a volume of about 1.347 mm based on POCASA 1.1. The average depth is The cavity has the potential to bind small molecules.

[0027] The application website of Alphafold 2 is: (AlphaFold Protein Structure Database, http: / / alphafold.com), and the application website of Discovery studio is: BIOVIA Discovery Studio|Dassault Systèmes (3ds.comhttps: / / www.3ds.com / products / biovia / discovery-studio). See the attached Figure 1 , A shows that the structure of human FGL2 protein is quite different from that of chicken Fibronogen, because chicken FGL2 does not have a binding domain to the FcrIIR receptor. The structure of human FGL2 protein predicted by Alphafold2 software, C shows the characteristics of the FRED domain that was studied in detail.

[0028] Next, the inventors used the Schrodinger Glide software to perform virtual screening using molecular docking technology based on the pocket structure (cavity) in the structure of the hFGL2 protein obtained, evaluated the protein-small molecule binding ability of about 3 million small molecules in compound libraries such as Specs and ChemDiv, and screened drug-like structures based on the five rules of drug development and PAINS rules. The enriched structures were analyzed based on structural diversity and binding mode, and finally 50 to 100 compounds were selected for purchase and subsequent evaluation.

[0029] The inventors constructed methods based on surface plasmon resonance technology (SPR), isothermal titration calorimetry (ITC), microscale thermophoresis (MST), enzyme activity experiments, crystallography experiments, etc. to clarify the binding activity of small molecules obtained by virtual screening with hFGL2. According to the small molecule binding ability and structure-activity relationship data suggested by molecular docking, small molecules were modified using medicinal chemistry methods, and new specific hFGL2 lead compounds with excellent activity and strong selectivity were discovered, providing new chemical entities for subsequent hFGL2 functional research and drug development.

[0030] Through the above research, the inventors screened and obtained 25 possible candidate molecules from the small molecule compound library, see attached Figure 2 .

[0031] Attached Figure 2 The candidate molecules obtained in the experiment may not bind to FGL2 in real situations, or even if they can bind, their interference effect is lacking or low or even non-functional. Therefore, it is necessary to further enrich the number of candidate small molecule compounds and verify their interference effect.

[0032] The inventors extracted mouse spleen tissue, ground the tissue to obtain a single cell suspension, and used flow cytometry or magnetic bead sorting technology to obtain purified mouse naive CD3 + T cells.

[0033] Stimulation with anti-CD3 antibody combined with CD28 antibody CD3 + T cells were induced to activate and proliferate, and the cells were labeled with CFSE. After 48 hours, the cell proliferation was detected by flow cytometry.

[0034] In the above operation, mouse T lymphocytes were obtained by taking lymphocytes from mouse spleen and obtaining mouse T lymphocytes (magnetic bead negative selection). The steps of CFSE labeling T lymphocytes are as follows:

[0035] 1. Gently resuspend the cells in DPBS preheated at 37°C containing 1 μmol / mL CFSE to a cell concentration of 1x10 6 cell / ml (the original concentration of CFSE is 10 mM, which needs to be diluted 10,000 times);

[0036] 2. Incubate at 37℃ in the dark for 5 minutes, then add 5 times the volume of 1640 complete medium preheated at 37℃, mix well, incubate at 37℃ for 5 minutes (to terminate staining), centrifuge at 1500rpm for 5 minutes, and discard the supernatant. Resuspend the cells with preheated 1640 complete medium, incubate at 37℃ for 10 minutes, centrifuge at 1500rpm for 5 minutes, discard the supernatant, resuspend the cells with preheated 1640 complete medium, centrifuge at 1500rpm for 5 minutes, and discard the supernatant;

[0037] 3. Then use 1640 complete component culture medium containing 10% fetal bovine serum to adjust the cell concentration to 1x10 6 cell / ml.

[0038] The steps of T cell activation (CD3 / CD28 beads activation method) are as follows:

[0039] 1. Wash the magnetic beads: resuspend the magnetic beads in the vial (vortex > 30 seconds), transfer the required volume of magnetic beads to the tube, add an equal amount of MACS buffer, or at least 200ul, mix (vortex for 5 seconds, or pipette to mix), and place the test tube on the magnetic stand for 1 minute;

[0040] 2. Add magnetic beads (the ratio of magnetic beads to cells is 1:1, as shown in the table below) to the cell suspension and mix well.

[0041]

[0042] Activated CD3 + T cells were labeled with CFSE and analyzed by flow cytometry 48 h later for the inhibition of CD3 T cells by sFGL2 through its receptor FcγRIIB. + T cell proliferation.

[0043] In the study, it was determined that sFGL2 inhibited CD3 through its receptor FcγRIIB. + Under the premise of T cell proliferation, anti-CD3 antibody + CD28 antibody + sFGL2 stimulation CD3 + T cells were added Figure 2The small molecule compounds in the experiment were 10 μM each, and the cells were labeled with CFSE. After 48 hours, the effects of the small molecule compounds on CD3 + Regulation of T cell proliferation.

[0044] The steps for plating sFGL2 and compound addition are as follows:

[0045] 1. Take the U-bottom 96-well plate as an example. The plate needs to be rinsed with PBS first, and 8×10 4 cells, 150ul RPMI-1640 complete medium;

[0046] 2. Blank group: blank control cells + 0.15ul DMSO

[0047] Stim group: CFSE-stained cells + 2ul beads + 0.15ul DMSO

[0048] fgl2 group: CFSE-stained cells + 5ug / mL fgl2 + 0.15ul DMSO

[0049] Stim+fgl2 group: CFSE-stained cells+2ul beads+5ug / mL fgl2+0.15ul DMSO

[0050] Stim+fgl2+compound group: CFSE-stained cells+2ul beads+5ug / mL fgl2+10uM compound (the original concentration of the compound is 10mM, which needs to be diluted 1000 times)

[0051] 3. Spread evenly into the well plate and place in the incubator for 48 hours.

[0052] See attached Figure 3 The experimental results showed that a total of 8 drug treatments, including No. 4, 10, 11, 16, 17, 21, 22, and 23, could restore T cell proliferation ability by interfering with FGL2 activity.

[0053] To further verify the drugability of the small molecule compound obtained above, the inventors further diluted the concentration of the compound from 10 μM to 1 μM, the steps are as follows:

[0054] 1. Take the U-bottom 96-well plate as an example. The plate needs to be rinsed with PBS first, and 8×10 4 cells, 150ul RPMI-1640 complete medium;

[0055] 2. Solution:

[0056] Blank group: blank control cells + 0.15ul DMSO

[0057] Stim group: CFSE-stained cells + 2ul beads + 0.15ul DMSO

[0058] fgl2 group: CFSE-stained cells + 5ug / mL fgl2 + 0.15ul DMSO

[0059] Stim+fgl2 group: CFSE-stained cells+2ul beads+5ug / mL fgl2+0.15ul DMSO

[0060] stim+fgl2+compound group (4, 10, 11, 16, 17, 21, 22, 23): CFSE-stained cells+2ul beads+5ug / mL fgl2+1uM compound;

[0061] 3. Evenly spread the cells in the well plate and place them in the incubator for 48 hours;

[0062] 4. After incubation, add 150ul FACS solution to each well, mix well to terminate staining, centrifuge at 1700rpm for 5min, discard the supernatant, add 200ul FACS solution to resuspend the cell pellet; centrifuge at 1700rpm for 5min, discard the supernatant, add 200ul FACS solution to resuspend the cell pellet, transfer to the flow tube, and detect on the machine.

[0063] See attached Figure 4 , it can be seen that No. 16 (C 16 H 17 N3O2 (ChemDiv Product No.: Y206-1674)) and 17 (C 14 H 16 N2O2S2 (ChemDiv product number: Y206-8392)) at a concentration of 1 μM may restore T cell proliferation ability by interfering with FGL2 activity.

[0064] Based on the above results, the inventors further used molecular docking technology to analyze the 16 H 17 N3O2) compounds and 17(C 14 H 16 The binding effect of N2O2S2) compounds on mouse FGL2 is shown in the attached Figure 5 The results showed that both compounds could stably bind to mouse FGL2.

[0065] Example 2: Treatment with small molecule compounds inhibits the progression of liver cancer transplant models

[0066] Since FGL2 is expressed in liver cancer and liver with the highest abundance, the inventors established a liver cancer transplant model and analyzed the expression of FGL2 in 16 (C 16 H 17 N3O2) and No. 17 (C 14 H 16 The regulatory effect of small molecule compounds of N2O2S2 on the progression of liver cancer. The cell line Hepa1-6-Luc-puro used in this example was purchased from Yimo Biotechnology, and SPF-grade C57BL / 6 (WT) mice were purchased from Beijing Sibeifu Biotechnology Co., Ltd., all of which were 6 to 8 weeks old and weighed 17 to 22 g. The animal experiments involved in this example were in accordance with the animal research protocol approved by the Experimental Animal Welfare and Ethics Committee of the Army Medical University.

[0067] Prepare 20% urethane anesthetic solution with physiological saline and inject it intraperitoneally at 1500 mg / kg. Adjust the Hepa1-6-Luc-puro cells to 5×10 7 After the mouse is fully anesthetized, the abdominal cavity of the mouse is exposed, the liver lobe of the mouse is squeezed out, and 20 μl of the cell suspension (about 10 6 cells / each) were injected into the exposed liver lobe. At the same time, mice were intraperitoneally injected with 16 (C 16 H 17 N3O2)(1mg / kg); and No. 17(C 14 H 16 N2O2S2)(1mg / kg).

[0068] In vivo imaging to observe tumor size: After 7 days (observed every three days), the wounds of the mice were basically healed, and the tumor size could be observed by in vivo imaging. The in vivo imaging results were analyzed using Living Image 4.4 software, and the immunohistochemistry results were quantified using Image J software. The experimental data were expressed as mean ± standard deviation, and GraphPad prism8.0 software was used for difference analysis and mapping. The Unpaired t test was used to compare the two samples; p < 0.05 was considered statistically significant. At the same time, the mice were weighed and marked.

[0069] In the process of tracking phenotypic differences in the liver cancer model constructed by the above-mentioned Hepa1-6-Luc-puro cell line, it was found that the model mice showed abnormal behaviors such as hunched back, isolation, and slow activity about three days after surgery, while the small fraction compound C 16 H 17 N3O2 and small molecule compound C 14 H 16 Mice treated with N2O2S2 did not experience similar phenomena, and their activities were normal without other abnormalities.

[0070] See attached Figure 6 In vivo imaging results showed that the small fraction compound C 16 H 17 N3O2 and small molecule compound C 14 H 16 N2O2S2 can inhibit the progression of the intrahepatic transplanted tumor model. Figure 7 On the tenth day after treatment, the 16 H 17 N3O2 and small molecule compound C 14 H 16 The size of liver cancer treated with N2O2S2 was smaller, indicating that the small molecule compound C 16 H 17 N3O2 and small molecule compound C 14 H 16 N2O2S2 has a significant inhibitory effect on the progression of liver cancer in vivo.

[0071] Example 3: Single-cell transcriptome sequencing analysis of the potential mechanism of small molecule compound treatment regulating liver cancer progression

[0072] The inventors conducted single-cell sequencing analysis on liver cancer tissues of C57BL / 6 mice, grouped the cells, and then continued to perform differential analysis, GO function enrichment, and KEGG pathway enrichment on the main affected cell populations to further analyze the potential mechanism by which small molecule compound treatment affects the occurrence and development of liver cancer.

[0073] The results showed that endothelial cells and B cells accounted for a large proportion in normal liver tissue, while T cells and macrophages were dominant in cancer tissue. In addition, compared with the Mock-treated mice, the immune cells infiltrating the cancer tissue after modeling were significantly higher in the small molecule compound C. 16 H 17 N3O2 and small molecule compound C 14 H 16 N2O2S2 treatment can lead to CD8 + The number of T cells, macrophages, monocytes and neutrophils in vivo increased significantly, indicating that the small molecule compound C 16 H 17 N3O2 and small molecule compound C 14 H 16 Both N2O2S2 can antagonize tumor progression by blocking the sFGL2 signaling pathway.

[0074] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution, which should be included in the scope of the claims of the present invention.

Claims

1. An anti-tumor small molecule compound targeting FGL2, characterized in that: The small molecule compound is C 16 H 17 N3O2 and C 14 H 16 Any of N2O2S2.

2. The anti-tumor small molecule compound targeting FGL2 according to claim 1, characterized in that: The tumor is a liver tumor.

3. The anti-tumor small molecule compound targeting FGL2 according to any one of claim 1 or claim 2, characterized in that: The small molecule compound was used at a concentration of 1 μM.

4. The anti-tumor small molecule compound targeting FGL2 according to any one of claim 1 or claim 2, characterized in that: The small molecule compound is tightly bound to the FGL2 protein by inserting into the pocket of the fibrinogen-related domain composed of 233 amino acids at the C-terminus of the FGL2 protein.

5. Use of the small molecule compound according to any one of claims 1 to 4 in the preparation of a drug for treating tumor diseases with high expression of FGL2.

6. The use according to claim 5, characterized in that: The drug interferes with the binding of FGL2 to its receptor FcγRIIB by binding to FGL2, thereby promoting T cell proliferation and differentiation.

7. The use according to claim 5, characterized in that: The drug binds to FGL2 and interferes with the binding of FGL2 to its receptor FcγRIIB, thereby interfering with the activation of myeloid-derived immunosuppressive cells, thereby inducing tumor clearance.

8. The use according to claim 5, characterized in that: The drug can also be used to treat severe hepatitis.

Citation Information

Patent Citations

  • Application of hfgl2 (Human Fibrinogen-like protein 2) inhibitor in preparation of medicaments for treating liver cancer

    CN102085378A

  • Low-toxicity 1,8-naphthalimide derivative and synthetic method and application thereof

    CN108147995A

  • Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

    WO2001098290A2

  • Allosteric JNK inhibitors

    WO2010108115A1